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Epigenetic alternations significantly contribute many disease progressions as the 
genetic changes do. However, there is a crucial difference between genetic and 
epigenetic alterations, which has important implications for development of cancer 
treatments. Therefore it is tough duty and also necessary to identify the all pathways 
or mechanism by which they work for the development of strategies to impede their 
abnormal behaviours. 
Chromatin condensation or relaxation is closely linked with tumorigenesis or cancer 
by regulating the pattern of gene expression. Methylation is often associated with 
silencing of many genes. Polycomb group proteins are important for the somatic 
maintenance of imprinting and for maintaining the silenced state of homeotic genes. 
The frequent deregulation of PcG activities in human tumors has direct oncogenic 
effects and results essential for cancer cell proliferation. Ezh2, a Polycomb group 
protein is the catalytic subunit of PRC2 having conserved SET domain targets 
H3K27me3. There is little contribution of Ezh2 is known till this date, still 
H3K27me3 and DNA methylation play a role together in gene silencing by loss of 
tumor suppression. Ezh2 also linked to histone deacetylation and it is shown that 
HDAC which is associated to EED is required for PRC2 to perform its function. 
Here we investigate the functional role of EZH2 in lymph node and gall bladder 
cancer progression. EZH2 and SUZ12 transcripts were consistently elevated in lymph 
node carcinoma as compared with normal blood cell. Band intensity analysis 
demonstrated that EZH2 and SUZ12 protein levels were strongly associated with 
lymph node cancer aggressiveness. HDAC overexpression in tis cancer supports the 
EZH2-mediated cell invasion required an intact SET domain and histone deacetylase 
activity. This study provides the functional link between H3K27me3, DNMTs and 





E(Z): Enhancer of Zeste 
EZH2: Enhancer of Zeste homolog 2 
EED: Embryonic ectoderm development 
ESC: Extra sex combs 
HMT: Histone methyltransferase 
PcG: Polycomb group 
PRC: Polycomb repressive complex 
SAM: S-Adenosyl methionine 
SUZ: Suppressor of Zeste 
TrxG: Trithorax group 
Xi: X chromosome inactivation 
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DNMT:             DNA methyltransferase 
HCAC:             Histone deacetylase 
PCR:             Polymerase chain reaction 
SET:             Su(var) Enhancer of Zeste Trithorax 
HAT:             Histone acetyltransferase 
NuRD:             Nucleosome remodelling 
CDK:             Cyclin dependent kinase 
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1.1. Hallmarks of Cancer 
Cancer has been discovered centuries ago but it remains a mystery till today. Cancer 
is ultimately the result of cells that uncontrollably grow and do not die. Normal cells 
in the body follow an orderly path of growth, division, and Programmed cell death is 
called apoptosis, and when this process breaks down, cancer begins to form. Unlike 
regular cells, cancer cells do not experience programmatic death and instead continue 
to grow and divide. Cancer harms the body when damaged cells divide uncontrollably 
to form lumps or masses of tissue called tumors (except in the case of leukemia where 
cancer prohibits normal blood function by abnormal cell division in the blood stream). 
Hanahan and Weinberg proposed in their classic review (2000), six essential 
hallmarks that collectively dictate malignant growth: (1) self-sufficiency in growth 
signals, (2) insensitivity to growth-inhibitory signals, (3) evasion of apoptosis, (4) 
limitless replicative potential, (5) sustained angiogenesis, and (6) tissue invasion and 
metastasis [1]. Recently, the same authors added two new hallmarks and two enabling 
characteristics, which have gained increasing importance during the progress of 
cancer research. The two enabling characteristics are genomic instability and tumour-
promoting inflammation, while the two new hallmarks are deregulation of cellular 
energetics and avoidance of immune destruction. 
 
 
Fig: 1. Acquired capabilities of Cancer (Hanahan and Weinberg, 2000) 
 
  
Epigenetic alternations significantly contribute many disease progressions as the 
genetic changes do. However, there is a crucial difference between genetic and 
epigenetic alterations, which has important implications for development of cancer 
treatments. Mutation results in the permanent change in the DNA sequence which is 
very tough to recover or counteract but the epigenetic changes is transient and can be 
reversed by the antagonists. Chromatin condensation or relaxation is closely linked 
with tumorigenesis or cancer by regulating the pattern of gene expression. Therefore 
it is tough duty and also necessary to identify the all pathways or mechanism by 
which they work for the development of strategies to impede their abnormal 
behaviours. The site of epigenetic alternations mainly focused on DNA methylation at 
CpG island but methylation of histones are also implicated in oncogenesis. 
 
1.2. Cancer as an Epigenetic disease 
Much effort has been invested in identifying genetic mutations in cancer.  In inherited 
cancer syndromes this approach has proved successful.  Furthermore, mutations early 
in the genesis of common cancers have also been identified and these are likely to be 
associated with tumour initiation.  In contrast, few specific genetic mutations have 
been linked to tumour progression, leading Feinberg to suggest that epigenetic 
changes may be involved. Epigenetic changes occur without a change in the DNA 
sequence and they can be induced by various factors. Thus it is possible, for example, 
that a DNA mutation leads to cellular transformation, but induced changes in the 
epigenome of the transformed cell enhances the probability that it will be capable of 
metastasising [2]. 
Cancer is an epigenetic disease at the same level that it can be considered a genetic 
disease. In fact, epigenetic changes, particularly DNA methylation, are susceptible to 
change and are excellent candidates to explain how certain environmental factors may 
increase the risk of cancer. The delicate organization of methylation and chromatin 
states that regulates the normal cellular homeostasis of gene expression patterns 
becomes unrecognizable in the cancer cell. The genome of the transformed cell 
undergoes simultaneously a global genomic hypomethylation and a dense 
hypermethylation of the CpG islands associated with gene regulatory regions. These 
dramatic changes may lead to chromosomal instability, activation of endogenous 
parasitic sequences, loss of imprinting, illegitimate expression, aneuploidy, and 
mutations, and may contribute to the transcriptional silencing of tumour suppressor 
genes. The hypermethylation-associated inactivation affects virtually all of the 
pathways in the cellular network, such as DNA repair, the cell cycle, and apoptosis. 
The aberrant CpG island methylation can also be used as a biomarker of malignant 
cells and as a predictor of their behaviour, and may constitute a good target for future 
therapies. 
  
In this scenario, a genetic mutation initiates the cancer but epigenetic change 
promotes its progression. Epigenetic processes may also be involved in cancer 
initiation.  It is possible that epigenetic change may lead directly to cancer initiation. 
Alternatively, changes already induced within the epigenome may 'prime' cells in 
such a way as to promote cellular transformation upon a subsequent DNA mutagenic 
event. In this case the epigenetic component of the cancer initiation is intricately 
entwined with the genetic component.  The involvement of epigenetic change in 
cancer initiation is of course not mutually exclusive to it having also a role in cancer 
progression. 
A genetic alteration in the gene encoding an 'epigenetic enzyme' (e.g. a histone 
acetyltransferase, histone methyltransferase) may lead to changes within the 
epigenome.  If, for example, these changes cause the activation of an oncogene then 
cancer may arise.  In addition, mutations in genes that code for proteins that recognize 
and bind to epigenetic marks (e.g. methyl binding domain proteins and bromo/chromo 
domain proteins which bind to methylated DNA and acetylated/methylated histones 
respectively) could be as important in cancer as mutations in the enzymes themselves.  
Although these are genetic events that lead to cancer, an alteration in the epigenome 
most likely also plays a part.  However, it should be noted that many of the histone-
modifying enzymes also modify non-histone proteins, thus making a direct link 
between enzyme deregulation, changes in the epigenome and cancer extremely 
difficult. 
DNA methylation was the first epigenetic alteration to be observed in cancer cells5. 
Hypermethylation of CpG islands at tumour suppressor genes switches off these 
genes, whereas global hypomethylation leads to genome instability and inappropriate 
activation of oncogenes and transposable elements1. It appears that genomic DNA 
methylation levels, which are maintained by DNMT enzymes, are delicately balanced 
within cells; over-expression of DNMTs is linked to cancer in humans, and their 
deletion from animals is lethal [3]. Furthermore, methyl cytosine is capable of 
spontaneously mutating in vivo by deamination to give thymine.  Indeed, 37% of 
somatic p53 gene mutations (and 58% of germ-line mutations) occur at methyl CpGs 
and these mutations are strongly implicated in the cause of cancer [4]. 
The histone N-terminal histone tails are crucial in helping to maintain chromatin 
stability and they are subject to numerous modifications.  Most modifications have 
some role to play in transcriptional regulation and so each has the potential to be 
oncogenic if deregulated deposition leads, for example, to loss of expression of a 
tumour suppressor gene [2,3]. 
Histone acetylation tends to open up chromatin structure.  Accordingly, histone 
acetyltransferase (HATs) tend to be transcriptional activators whereas histone 
deacetylases (HDACs) tend to be repressors.  Many HAT genes are altered in some  
  
way in a variety of cancers [3].  For instance, the p300 HAT gene is mutated in a 
number of gastrointestinal tumours.  On the other hand, alteration of HDAC genes in 
cancer seems to be far less common.  However, despite this low incidence of genetic 
mutation in cancer, HDAC inhibitors are performing well in the clinic as anti-cancer 
drugs. 
Histone methylation:  All lysine methyltransferases that target histone N-terminal 
tails contain a so called SET domain.  This domain possesses lysine methyltransferase 
activity and numerous SET domain-containing proteins are implicated in cancer [5,6].  
One example is the Suv39 family of enzymes that catalyse methylation of H3K9.  
Transgenic mice devoid of these enzymes are very susceptible to cancer, especially B 
cell lymphomas.  Histone demethylases have only very recently been identified and as 
yet no linkage to cancer has been observed.  However, such a linkage seems probable. 
 
Fig: 2. Mechanism of Lysine and Arginine methylation.                                         
http://genesdev.cshlp.org/content/15/18/2343/F2.small.gif 
 
Histone phosphorylation:  H3S10 and H3S28 are phosphorylated at mitosis - a 
crucial part of the cell cycle; misregulation here is often associated with cancers.  




An early event following DNA damage is the phosphorylation of H2AX, a process 
that is required for efficient DNA repair.  If repair is not performed correctly the cell 
is left with damaged DNA, with predictable consequences. 
 
1.3. Inheritance of Epigenetic marks 
Epigenetic inheritance is defined as cellular information, other than the DNA 
sequence itself that is heritable during cell division [3]. Epigenetics affect the 
transcription in the cell, thereby controlling gene expression and abnormal epigenetic 
changes can have serious effects for the organism. 
Although substantial detail about the inheritance of DNA methylation through mitotic 
cell division is known, any analogous mechanisms for the inheritance of histone 
modifications are not as clearly understood. Histone Lysine methylation does not 
appear to turnover quickly and presumably persists through cell division. Even for 
highly dynamic modifications such as acetylation, earlier studies showed that specific 
sites of acetylation are maintained during mitosis, and such inheritance of acetylation 
patterns is thought to maintain the expression profiles of genes through successive 
generations [7,8]. 
 
Early studies using radioactively labelled histones strongly suggested that the parental 
histones are transferred as intact octamers, and are randomly segregated onto the two 
daughter DNA strands [9,10]. Nucleosome assembly complexes then deposit 
additional newly synthesized histones to fill in the gaps. Interestingly, a recent report 
suggested that the parental nucleosomes may actually divide in a semiconservative 
manner whereby the parental histone octamer is split into H2A-H2B/H3-H4 
heterodimers that are then equally segregated onto the two daughter DNA strands 
[11]. In this scenario, the nucleosome assembly complex then deposits newly 
synthesized histones to complete the pre-existing half of the nucleosome. This idea is 
intriguing because it invokes the possibility of a mechanism that can faithfully and 
equally transmit histone-associated information from parent to daughter DNA strands. 
However, it is not clear how this hypothesis fits in with earlier data that showed 
transfer of intact histone octamers during DNA replication. 
 
At present, a similar process for replicating histone modification has not been shown. 
Nevertheless, it is interesting to note that some HMTs such as EZH2 also contain 
chromodomain motifs that potentially have a role in targeting these enzymes to 
selectively modified regions of chromatin. Also, several HATs such as CBP and 
p300/CBP associated factor also contain bromodomains, a motif that has been shown 
to have acetyl-Lys binding properties [12]. Whereas the chromo and bromodomains 
of these HMTs and HATs have not yet been found to bind specific methylated or  
 
  
acetylated histones, the functional significance of these potential modification binding 
motifs present on histone methyl and acetyltransferases is yet out of reach. 
 
1.4. Histone methylation and Chromatin structure 
Methylation plays dual roles in regulating histone accessibility as it has been linked to 
both activation and silencing of transcription [13]. Methylation confers additional 
levels of complexity as methylation can be mono, di- or tri- methylation and occurs at 
lysine (K) and arginine residues. Methylation of arginine residues has been linked to 
gene activation while lysine methylation has been linked with gene silencing and 
activation [14,15]. Arginine is a positively charged amino acid and the nitrogen of 
arginine can be modified by the addition of one or two methyl groups. Currently eight 
mammalian protein arginine methyltransferases have been identified.  While the 
mechanism through which arginine methylation enhances transcription remains 
unknown, evidence exists that methylated arginines collaborate with other 
transcriptional activators and enhance their activity to promote transcriptional 
activation. Methylation on lysine residues generally correlates with gene suppression 
but can also contribute to gene activation. One, two or three methyl groups can be 
added by histone methyltransferases (HMTases). Trimethylation of histone 3 lysines 9 
and 27 or histone 4 lysine 20 35 is associated with gene silencing, while H3K4 di- and 
trimethylation, H3K36 trimethylation, and H3K79 di- and trimethylation methylation 
contributes to gene activation [16].  
In higher eukaryotes, histone methylation is involved in the maintenance of cellular 
identity during somatic development. During spermatogenesis, most nucleosomes are 
replaced by protamine. Therefore, it is unclear if histone modifications function in 
paternal transmission of epigenetic information. Here we show that active H3K4 di-
methylation (H3K4me2) and repressive H3K27 trimethylation (H3K27me3), two 
modifications important for Trithorax and Polycomb-mediated gene regulation, are 
present in chromatin of human spermatozoa and show methylation-specific 
distributions at regulatory regions. H3K4me2-marked promoters control gene 
functions in spermatogenesis and cellular homeostasis suggesting that this mark 
reflects germline transcription. In contrast, H3K27me3 marks promoters of key 
developmental regulators in sperm as in soma. Many H3K27me3-marked genes are 
never expressed in the male and female germline, and in early “totipotent” embryos, 
suggesting a function for Polycomb in repressing somatic determinants across 
generations. Targets of H3K4me2 and H3K27me3 are also modified in mouse 
spermatozoa, implicating an evolutionary conserved role for histone methylation in 
chromatin inheritance via the male germline. 
The histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2) belongs to 
Polycomb Group (PcG) and is involved in gene repression [17]. EZH2 catalyzes  
  
trimethylation of H3K9 and H3K27 with a strong preference for K27 [18]. EZH2 has 
a cysteine rich SET domain which is involved in binding to the Polycomb repressive 
complex [18]. EZH2 binds to the CIITA proximal promoter and is a “master 
regulator” of the silencing histone modifications at CIITApIV, thus implicating roles 
for EZH2 in regulating other silenced, but inducible genes. Of note are recent studies 
indicating expression of EZH2 is elevated in multiple human cancers, including breast 
cancer. 
While the mechanisms by which histone methylation contributes to gene silencing are 
not known, cross talk between various modifications has been observed (Muller and 
Verrijzer 2009).  H3K4 methylation blocks methylation of H3K9 and induces the 
dimethylation of H3K27, resulting in an opening of chromatin structure [19]. H3K36 
methylation recruits histone deacetylases and re-establishes closed structure resulting 
in decreased gene expression. Similar to reversible acetylation, histone methylation 
can also be reversed by histone demethylases (HDMTs).  The first identified HDMT 
is LSD1 which demethylates mono- and di- H3K4 in a flavin adenine dinucleotide 
(FAD) dependent oxidative reaction. This observation led to discovery of highly 
conserved Jumonji C containing proteins which remove methyl groups from lysine 
residues. This recent observation that methylation is reversible by histone 
demethylases provides new levels of regulation for gene expression. There are also 
additional interactions between methylated histones and the DNA methylation 
machinery which further determines the availability of DNA for gene expression. 
While histone methylation and the impact on DNA structures is reversible, DNA 
methylation is permanent and leads to stable repression of gene expression. The 
interactions between methylated histones and methylated DNA are complex as 
histone methylation mediates DNA methylation and DNA methylation also serves as 
a template for modifications to histones. Greater understanding of the crosstalk 
between modifications to histones and modifications to DNA provide new, and 
largely unexplored, levels of regulation of gene. 
 
1.5. Role of SET domain in histone methylation 
Structural-functional analysis of Suv39H1 showed that its HMT activities are 
mediated by the SET domain of the proteins. This highly conserved domain is found 
in large number of proteins from yeast to human, and is named after the three 
founding proteins that share this domain: Su(VAR)3–9, enhancer of Zeste [E(Z)], and 
trithorax (TRX) [22]. Indeed, all three of these proteins, as well as a growing number 
of other SET domain-containing proteins, have now been shown to have HMT 
activities and they each have exquisite specificity toward different sites on H3 or H4 
[24]. E(Z) and TRX belong to the Polycomb (Pc)- and trx-group gene product 
families that have previously  been  identified  as  chromatin-modifying  proteins  
  
important for maintaining the balanced expression of homeotic genes in Drosophila 
and mammals. The human EZH2 methylates histone H3 at Lys27, whereas the TRX 
homologs [for example, Set1p in S. cerevisiae, TRX, TRR (trithorax-related) in 
Drosophila, and MLL (myeloid or mixed lineage leukemia) in human] all methylate 
H3 at Lys4 [24]. Consistent with the previously assigned roles of the Pc and trx 
complexes in transcriptional repression and activation, respectively, H3 Lys27 
methylation has been correlated with transcription silencing, and H3 Lys4 
methylation is now well established as a chromatin mark for active genes. Analogous 
to the binding of the chromodomain of HP1 to Lys9-methylated H3, the 
chromodomain of the Pc protein has been found to bind Lys27-methylated H3, and 
functions to recruit the Pc complex to initiate Pc-dependent transcriptional silencing 
[26]. Interestingly, swapping of the chromodomain of HP1 and Pc was sufficient to 
switch the nuclear localization of these proteins in Drosophila S2 cells, indicating that 
the binding of the respective chromodomain of these proteins to the Lys9- or Lys27-
methylated H3 has important roles in the targeting of chromatin-binding proteins in 
vivo. 
H3 Lys4 methylation has been well documented to be associated with euchromatic 
regions in diverse organisms including S. pombe, Drosophila, and mammalian cells; 
however, a direct role for this modification in activating transcription has not been 
found. Biochemical pull-down assays showed that Lys4- methylated H3 can bind to 
the chromatin remodelling enzyme Isw1p [26]. In addition, association of Isw1p to 
chromatin is dependent on the H3 Lys4-methylating enzyme Set1p in S. cerevisiae, 
suggesting that this modification promotes association of remodelling factors that in 
turn facilitate transcription. Biochemical data also suggested that Lys4-methylated H3 
can prevent binding of the mammalian HDAC complex NuRD (nucleosome 
remodelling and HDAC) to chromatin [25]. The consensus so far suggests that H3 
Lys4 methylation may have an indirect regulatory role by maintaining the associated 
genomic regions in a state that is poised for transcription activation. 
 
1.6. Role of Su(var) in histone methylation 
It has long been known that histones, particularly H3 and H4, are methylated at a 
number of lysine (Lys) and arginine (Arg) residues. The major sites of Lys-
methylation on histones identified so far are: Lys4, Lys9, Lys27, Lys36, Lys79 on H3 
and Lys20 on H4 [20,21]. In addition, the Lys residue can be methylated in the form 
of mono-, di-, or trimethylation, and this differential methylation provides further 
functional diversity to each site of Lys methylation. A major breakthrough in the 
understanding of H3 Lys-methylation function was the discovery that one of the well-
studied Su(var) genes in fact encodes a histone methyltransferase (HMT). The 
Su(var)3–9 gene in Drosophila, and its homolog, Clr4, in fission yeast S. pombe, were  
  
originally identified by genetics screens to have roles in transcriptional silencing 
associated with heterochromatin (in Drosophila) and mating type silencing (in S. 
pombe) [22]. Biochemical analyses of the human homolog, Suv39H1, revealed that 
this protein has an enzymatic activity that specifically methylates histone H3 at Lys9 
[23]. This finding, followed by a convergence of genetics and biochemical data, and 
aided by the development of antibodies highly specific for H3 methylated at different 
sites, quickly delineated a pathway of heterochromatin formation. 
In mouse, disruption of the two Su(var)3–9 homologs, Suv39h1 and Suv39h2, led to 
impaired viability and chromosomal instabilities in the double-null mouse embryos 
[24]. By using antibodies that specifically distinguish the mono-, di- and 
trimethylation state of Lys9- methylated H3, it was found that fibroblasts derived 
from the dn embryos show a specific loss of the Lys9 trimethylated form of H3 at 
pericentric heterochromatin [25]. Interestingly, whereas HP1 localization in these 
cells is compromised, the presence of condensed chromatin at pericentric regions, as 


















2. REVIEW OF LITERATURE 
2.1. Housekeeping functions of EZH2 
Polycomb group (PcG) and trithorax group (trxG) proteins are well known to be part 
of the cellular memory system [27,28]. Both groups of proteins are involved in 
maintaining the spatial patterns of homeotic box (Hox) gene expression that are 
established early in embryonic development by the transient expression of 
segmentation genes. In general, PcG proteins are transcriptional repressors that 
maintain the ‗off state„, whereas trxG proteins are transcriptional activators that 
maintain the ‗on state„. Recent demonstrations that members of PcG and trxG 
proteins contain intrinsic histone methyltransferase (HMTase) activity raise the 
possibility that PcG and trxG proteins participate in cellular memory through 
methylating core histones [29]. 
 
2.1.1. Hox gene silencing 
The role of EZH2/EED complex, which includes histone deacetylation in 
transcriptional repression, is well documented. It has long been established that this 
complex can, for example, silencing of Hox genes. The EED-EZH2 complex, 
containing the core subunits EZH2, EED, SUZ12, and RbAp48, functions as a histone 
H3K27-specific methyltransferase. Here we describe the identification and 
characterization of a related EED-EZH2 protein complex which is distinguished from 
the previous complex by the presence of another PcG protein, hPHF1. Consistent with 
the ability of hPHF1 to stimulate the enzymatic activity of the core EED/EZH2 
complex in vitro, manipulation of mPcl1, the mouse counterpart of hPHF1, in NIH 
3T3 cells and cells of the mouse male germ cell line GC1spg results in global 
alteration of H3K27me2 and H3K27me3 levels and Hox gene expression. Small 
interfering RNA-mediated knockdown of mPcl1 affects association of the EED/EZH2 
complex with certain Hox genes, such as HoxA10, as well as Hox gene expression 
concomitant with an alteration on the H3K27me2 levels of the corresponding 
promoters [30]. Therefore, our results reveal hPHF1 as a component of a novel 
EED/EZH2 complex and demonstrate its important role in H3K27 methylation and 
Hox gene silencing. 
 
2.1.2. X-chromosome inactivation 
Another most important function of EZH2 is X-chromosome inactivation, is a 
developmentally regulated process involving choice of the active X chromosome, 
initiation of silencing on the Xi and maintenance of silencing throughout all 
subsequent cell divisions [31]. Xist, a noncoding RNA transcript, coats the Xi and is  
 
  
thought to mediate its silencing [32]. Studies over the past several years have shown 
that several epigenetic modifications,  
 
including histone H4 hypoacetylation, enrichment of the variant histone macroH2A 
and DNA methylation, are features of the Xi [32]. An EED–EZH2 histone 
methyltransferase complex was first implicated in X-inactivation when mice 
homozygous for an EED mutation were found to be defective in maintaining X-
inactivation in extraembryonic, but not embryonic, tissues [31]. Consistent with a role 
of the EED–Ezh2 complex in X-inactivation in cells of extraembryonic lineage, EED 
and Ezh2 were found to be enriched on the Xist-coated Xi in trophoblast stem cells 
[32], an extraembryonic cell type. Two recent studies have further evaluated the role 
of EED–Ezh2-mediated H3- K27 methylation in X-inactivation [33]. 
 
Biochemical and genetic studies have provided compelling evidence that Drosophila 
PcG proteins function in two distinct protein complexes: the Polycomb repressive 
complex 1 (PRC1) and the Extra sex combs and Enhancer of Zeste (ESC–E[Z]) 
complex (also known as PRC2), although the dynamic compositions of the complexes 
are still controversial [33]. Similar protein complexes have also been described in 
mammals [34.35], underscoring the functional conservation of the PcG proteins 
during evolution. The discovery that the ESC–E[Z] complex (known as the EED–
EZH2 complex in mammals) contains intrinsic HMTase activity prompted the 
analysis of the role of histone methylation mediated by EED–EZH2 or ESC– E(Z) in 
PcG silencing, X-inactivation, germline and stem cell development, and cancer. Here 
we review recent progress in our understanding of the biochemical and biological 
functions of this complex and its associated enzymatic activity in these cellular 
processes. 
 
2.1.3. Stem cell pluripotency 
Recent studies suggest that Ezh2 and its associated H3-K27 methyltransferase activity 
might be important for maintaining stem cell pluripotency. Stem cells are 
characterized by their capacity for self-renewal and their ability to differentiate into 
all cell types. Characterization of stem cells has shown that several protein factors, 
including the POU domain homeobox transcription factor Oct3/4, are essential for 
stem cell pluripotency [36]. Oct3/4 is one of the earliest expressed transcription 
factors and is crucial for murine development at the preimplantation stage. It is 
expressed at high levels in stem cells such as embryonic germ cells, embryonic stem 
cells and embryonic carcinoma cells, but it undergoes rapid repression when these 
cells start to differentiate [37]. The first indication that murine Ezh2 might be linked 
to stem cell pluripotency came from the observation that Ezh2 is essential for the 
derivation of pluripotent embryonic stem cells [36]. Given the early embryonic lethal  
  
phenotype of Ezh2 mutants, and the fact that Ezh2 is a maternally inherited protein, 
the function of Ezh2 in preimplantation development is difficult to address. 
 
 
2.1.4. Germ line development 
The EZH2/EED complex is present throughout early preimplantation development in 
germ cells, oocytes and pluripotent stem cells in mice. The role of this protein 
complex is yet unclear. Here MES-2 (counterpart of Ezh2), MES-3 and MES-6 
(counterpart of EED) functions as a protein complex for transcriptional silencing. 
Recent studies reveal that MES-2/3/6 complex is responsible for H3K27me3, as this 
case with EZH2/EED complex in mice and human. Mutations in mes gene showed a 
marked alteration in H3K27me3 marks, which may explain the transcriptional 
silencing in the germ cell lineage. This PcG complex is also detected in mouse germ 
cell lineage from the time of specification and later when the germ cell lineage is 
established. The precise role of this protein in regulating the epigenetic status and 
maintenance of germ cell lineage remains to be elucidated [37]. 
 
2.2. EZH2 in Epigenetic scenario 
PcG proteins appear to perform their functions by forming complexes. Two distinct 
Polycomb complexes have been characterized by immunoprecipitation, yeast two- 
hybrid and size-fractionation experiments in mammalian system. BMI- 1, RING1, 
HPH1/2/3, and HPC1/2/3 [38] proteins constitute the Polycomb Repressive Complex 
1 (PRC1) and EZH2, EED, SUZ12, RbAp46/48 and AEBP2 (E(z), Esc, Su(z)12, and 
RbAp48 in Drosophila) [38] make the Polycomb Repressive Complex 2 (PRC2). The 
PRC2 was shown to physically associate with Yin Yang 1 (YY1, the human homolog 
of Pho in Drosophila) [39], which is the only known DNA binding protein of the 
Polycomb group, while all the others do not have apparent DNA binding motifs [40]. 
However, YY1 binding sites alone are not sufficient to alter the epigenetic pattern. It 
is shown that HDAC which is associated to EED [41] is required for PRC2 to perform 
its function. EZH2/E(z) contains a conserved histone methyltransferase domain, SET 
domain, named after SU(var)3-9, E(z) and Trithorax which contain this enzymatic 
domain [40]. Based on recent discoveries, a model is proposed to illustrate how 
Polycomb group complexes perform their function. At the beginning, the histone tails 
on the chromatin are acetylated and target genes are transcriptionally active. Once the 
cellular memory is disturbed, through the cell signaling pathway, PRC2 receives the 
signal from the cell signaling pathway and binds to a PRE. HDAC is then recruited to 
the PRE to deacetylate the histone tails, so that PRC2 can methylate the histone tails. 
This alters chromatin structure and enables PRC2 and HDAC to access the target gene 
promoters. Further, the histone tails on the gene promoters are deacetylated and then  
  
methylated. This methylation establishes a binding site for the N-terminal 
chromodomain of PcG proteins so that PRC1 is recruited to the promoters of target 
genes to repress their expression by repressing transcription initiation [42,43].  
Accordingly, PRC2 is also called PRCi (initiation), and PRC1 is called PRCm 
(maintenance). Human E(z) homolog EZH2 was initially identified as a protein 
associated with proto-oncogene VAV in lymphoma. The gene of EZH2 maps to 
chromosome 7q35 and consists of 20 exons, encoding 746 amino acid residues. By 
yeast two-hybrid screen with EZH2, human Esc homolog EED was identified to 
interact with EZH2 in vitro, and by co-IP, EZH2 and EED were confirmed to form a 
complex in vivo. Several studies demonstrated that the WD40 domains of EED are 
essential for this EZH2-EED complex, while the point mutants in the WD40 domain 
blocked the interaction between EZH2 and EED. Another polycomb protein SUZ12 is 
also characterized as an essential component of PRC2 for its HMTase enzymatic 
activity. Several interacting partners of the EZH2-EED complex include SUZ12, 
RbAp48 and AEBP2, which were identified by isolating and characterizing the 
enzymatic complex which had high HMTase activity to histone H3[44]. The 
reconstituted complex of EZH2, EED, SUZ12, RbAp48 and AEBP2 can specifically 
methylate Histone H3 in vitro. 
In 2002, Kuzmichev et al. found that PRC2 exhibited HMTase activity and could 
specifically methylate H3K9 and H3K27 [36]. Furthermore they proved that the 
methylation of H3K27 provides a mark for PRC1 protein PC1 binding, therefore, 
PRC1 is recruited to the targets. Generally the PRC2 protein EZH2 preferentially 
methylates Lysine 27 on histone 3 (H3K27) [38,39]. But under certain conditions, it 
can also methylate other substrates, such as H3K9 and H1BK26. Because EZH2 is the 
only known histone methyltransferase which can tri-methylate H3K27, the level of 
tri-me-H3K27 is used as the marker of EZH2 enzymatic activity. Some groups also 
reported that there exist Polycomb Repressive Complex 3 (PRC3) and Polycomb 
Repressive Complex 4 (PRC4) in cells [43,44]. The human EED has four different 
isoforms due to alternate translation initiation sites from the same mRNA. All of these 
isoforms can associate to EZH2 to form different complexes and bind to their 
substrates. EED1 (the largest isoform) and EZH2 form PRC2 (~400-kDa complex) 
and methylate H3K27 in the presence of histone H1. EED3 and EED4 (the two 
shortest isoforms) can form PRC3 (~400-kDa complex) with EZH2, and methylate 
H3K27 when histone 1 is absent. EED2, SirT1, which specifically binds to EED2, and 
EZH2 form PRC4 (~1.5-MDa complex) and methylate K26 residue on H1B. 
 
2.3. Cancer links to PRC2 subunits 
Less is known about cancer-associated alterations in PRC2 subunits besides EZH2, 
EED over-expression in human cancers has not been widely reported and the studies  
  
that first documented EZH2 over-expression in prostate and breast cancer revealed 
unchanged EED levels in the same patient samples [45]. There are also examples of 
SUZ12 alterations in cancer tissues including overexpression in colon, breast and liver 
tumors [45–47]. In addition, SUZ12 is implicated in endometrial cancer since a 
chromosome rearrangement creating a SUZ12 fusion protein is frequently associated 
with endometrial stromal tumors [46]. Finally, over-expression of PCL3, which is a 
homolog of the PRC2-associated protein, PHF1, is also associated with many cancers 
including colon, skin, lung and liver [47]. Since consequences of EZH2 
overabundance in cancer cells are still emerging, it is an open question if excessive 
levels of these non-catalytic partners work through similar mechanisms. 
 
Fig: 3. Polycomb Repressive Complex 2 (PRC2) binds to the PRE and function 
to repress the target gene. (www.nature.com/nature/journal/v469/n7330/images/nature09784-
f3.2.jpg) 
 
2.4. EZH2 mediates DNA methylation 
Epigenetics, the heritable regulation of gene expression independent of DNA 
sequence, is emerging as an essential aspect of the mechanisms of cell lineage 
determination and maintenance. DNA methylation and histone modification controls 
the epigenetic phenomena, particularly histone methylation. Current studies show the 
requirement of histone methylation for DNA methylation which is interconnected. 
 
Recently, Vire et al. reported that EZH2 can directly control DNA methylation, so 
that the two processes which can repress gene expression [39], Histone methylation 
and DNA methylation are connected, and this finding elucidates a mechanism by 
which Polycomb Group and DNA methyltransferases (DNMTs) work together to 
repress gene expression. The authors demonstrated that the complex pulled down with 
GST-EZH2 possesses DNMT activity and this complex contains EZH2, DNMT1, 
DNMT3A and DNMT3B, and that the N-terminal H-1 and H-II domains of EZH2 are 
 required for establishing and maintaining this complex. Furthermore, reciprocal 
coimmunoprecipitation (co-IP) confirmed that DNMTs interact with PRC2, EZH2 
and EED in vivo. Notably, similar to the effect of DNA methylation inhibitor 5„- 
azadeoxycytidine treatment, knock-down of EZH2, DNMT1, DNMT3A or DNMT3B 
markedly increases expression of their target genes, but not of the housekeeping 
genes. By ChIP in EZH2 RNAi cells, the authors demonstrated that EZH2 is essential 
for DNMTs recruiting to the promoters of their targets, while RNA polymerase II 
could interact with the promoters and turn on the expression of target genes. 
Several papers reported that PcG proteins are involved in the de novo DNA 
methylation in cancers or cancer cell lines. By ChIP analyses, it is shown that genes 
with DNA methylation in cancer are marked with Polycomb proteins. Interestingly, 
  
 
Fig: 4. Recruitment of HDAC and DNMTs by PRC2 for repression of target 
genes. (www.nature.com/nature/journal/v469/n7330/images/nature05344-f3.2.jpg) 
 
many tumor suppressors are repressed by active de novo DNA methylation, and are 
pre-marked with H3K27 tri-methylation, indicating the mechanism by which EZH2 
and PRC2 promote cancer progression. In normal tissues, some tumor suppressors are 
marked with H3K27 tri-methylation, but not de novo DNA methylation, 
demonstrating that EZH2 alone is not sufficient for DNA methylation, and several 
other components have to be recruited to methylate DNA to facilitate gene repression. 
Although EZH2 is required for DNA methylation, it is not required for maintaining 
DNA methylation and keeping the genes off. Some evidence demonstrated that 
knock-down of EZH2 can de-repress genes whose promoters are methylated, such as 
MYT1 and WNT1; But for the genes whose promoters are hypermethylated, such as 
MLH1, knockdown of EZH2 could not increase their expression, even though the 
H3K27 trimethylation level is decreased because of the EZH2 knockdown[47]. 
 
  
2.5. EZH2 and cancer 
It has been reported that increased expression of EZH2 had been associated 
previously with invasive growth and aggressive clinical behaviour in prostate and 
breast cancer (Su et al., 2003). Amounts of both EZH2 mRNA and EZH2 protein 
were increased in metastatic prostate cancer. In addition, clinically localized prostate 
cancers that expressed higher concentrations of EZH2 showed a poorer prognosis. 
Thus, Varambally et al. concluded that dysregulated expression of EZH2 may be 
involved in the progression of prostate cancer as well as being a marker that 
distinguishes indo- lent prostate cancer from those at risk of lethal progression 
(Dohner et al., 1998). EZH2 mRNA transcript and protein levels were elevated in 
invasive and metastatic breast cancer when compared to normal breast tissues 
(Rhodes et al., 2003). Higher EZH2 protein levels in the breast cancer were associated 
with a shorter disease- free interval after initial surgical treatment, lower overall 
survival, and a high probability of disease-specific death. Furthermore, the high EZH2 
levels were strongly associated with poor clinical out- come in breast cancer patients 
(Kleer et al., 2003). In 2005, Sudo et al. reported that EZH2 expression was 
significantly higher in human liver cancer cell lines and tissue specimens compared to 
normal sections (Sudo et al., 2005). Later, Chen et al. demonstrated that knock-down 
of EZH2 markedly inhibited the growth of hepatocellular carcinoma (HCC) cells and 
reduced the tumorigenicity of HCC cells in the nude xenograft mice. In bladder and 
gastric cancers, EZH2 was increased at both the mRNA and protein levels in cancer 
cell lines and cancer tissue specimens relative to normal controls. Several reports have 
been demonstrated that there is an inverse correlation between EZH2 and E-cadherin, 
which is a vital gene for controlling tumor invasion. Further studies indicated that E-
cadherin is key media- tor among the list genes that downstream of EZH2 regulation 
(Cao et al., 2008). 
 
2.5.1. EZH2 in Prostate cancer 
Prostate cancer is a leading cause of cancer-related death in males and is second only 
to lung cancer. Although effective surgical and radiation treatments exist for clinically 
localized prostate cancer, metastatic prostate cancer remains essentially incurable. 
Polycomb group protein enhancer of Zeste homolog 2 (EZH2) is over one of the 
earliest reports was a gene profiling study where EZH2 was scored as the most 
significant gene up-regulated in metastatic prostate cancer compared to clinically 
localized prostate cancer [35]. This study also showed that loss of EZH2 inhibits 
growth of prostate cancer cells. Similar requirements for EZH2 in proliferation of 
other cell types have been described [44]. Significantly, EZH2 over-expression in 
prostate cell lines led to silencing of a discrete set of >100 target genes, which was 
dependent upon an intact SET domain [35]. Thus, this work suggested that EZH2  
  
overabundance alters the genomic expression program through chromatin 
hypersilencing. Statistical analysis also revealed that EZH2 levels could provide a 
valuable prognostic indicator of patient outcome [35] and subsequent studies have 
described the prognostic value of combined sets of prostate markers that include 
EZH2 overabundance [50].More recently, a Polycomb repression “signature”, 
consisting of a cohort of 14 repressed EZH2 target genes, has been described as a tool 
for predicting prostate and breast cancer patient outcomes [50]. 
 
2.5.2. EZH2 in Breast cancer 
The role of EZH2 in breast cancer and demonstrated that EZH2 is elevated at both the 
transcript and protein levels in invasive and metastatic breast cancer when compared 
to normal breast tissues [51]. Immunohistochemical analyses performed on a 
spectrum of breast cancer tissues demonstrated that high EZH2 levels were strongly 
associated with poor clinical outcome in patients. Higher EZH2 protein levels were 
associated with a shorter disease-free interval after initial surgical treatment, lower 
overall survival, and a high probability of disease-specific death (i.e. death due to 
breast cancer). Also, high EZH2 expression was associated with disease-specific 
death in patients with lymph node-negative disease, but not in patients with positive 
lymph nodes. EZH2 expression was associated with disease-specific survival in 
patients with stage I and II disease, but not in patients with advanced stage (stages III 
and IV). Kaplan–Meier analysis showed that EZH2 levels were strongly associated 
with bad outcome in both ER positive and -negative invasive carcinomas suggesting 
that EZH2 has prognostic utility independent of ER status. 
Importantly, overexpression of EZH2 could increase HDAC enzymatic activity. Also 
overexpression of EZH2, but not the dominant negative mutant of EZH2, 
EZH2ΔSET, promotes anchorage-independent growth in epithelial cells [51]. The 
expression patterns of PRC1 and PRC2 are different in various stages of tumor 
progression. The PRC1 complex expression is always high in normal breast tissues, 
pervasive lesions and invasive breast carcinomas, which are consistent with the 
function of PRC1 to maintain the gene expression pattern. But in normal breast 
tissues, EZH2 and EED are rarely detectable except in the cycling cells. 
 
2.6. Applications of EZH2 
Synthetic peptide fragments of EZH2 were able to stimulate peripheral blood 
mononuclear cells (PBMCs) and produce EZH2-specific cytotoxic T lymphocytes 
(CTLs). Interestingly, those EZH2-specific CTLs can generate IgG against EZH2 and 
are toxic to HLA-A24 positive cells [46]. This finding provides an alternative 
approach to inhibit EZH2 function in cancer progression. 
  
Cyclin-dependent kinase 1/2(CDK1/2)-mediated Thr 350 phosphorylation as an 
important mechanism in control of EZH2-mediated epigenetic gene silencing in 
cancer cells. In turn, blockage of Thr 350 phosphorylation diminishes the global effect 
of EZH2 on gene silencing (Chen et al.) This discovery motivated us to find or design 
the inhibitors that can dephosphorylation of EZH2 to apply in the fields of cancer 
therapy. In context of Chen et al. report, CDK1/2 inhibitors could be served as a 
selective option for cancer therapy that blockage of phosphorylation of EZH2 [47]. 
 
Knockdown of EZH2 suppresses development of Ewing tumors in association with up 
regulation of genes involved in neuroectodermal/endothelial differentiation. These 
findings seem to indicate a key role for EZH2 in maintaining an undifferentiated 
phenotype in Ewing tumor. On the other hand, EZH2 is crucial in regulating cell cycle 
via the retinoblastoma pathway. 11,12,67,68 Knockdown of EZH2 deregulates genes 
involved in G2/M transition in a way that inhibits cell proliferation by inducing G2/M 
arrest [47]. The findings indicate that EZH2 overexpression results in decreased 
BRCA1 with high levels of Cdc2- CyclinB1 complex, which drives mitosis and 
uncontrolled proliferation. 
 
2.7. Targeting EZH2 for cancer therapy 
The enzymatic activity and its function as an epigenetic repressor along with its 
established role in cancer progression, makes EZH2 an attractive target for cancer 
therapy. S. Varambally et.al, shown that knock-down of EZH2 inhibits cancer cell 
growth, motility, invasion and tumorigenesis. Small interfering RNA against EZH2 
reduced EZH2 expression in several cancer cell lines, significantly inhibited cell 
proliferation and the cells were arrested at the G2/M phase [35]. In addition, the 
EZH2 knock down cells did not retain their invasive potential when injected into 
mice. This was apparent from the lack in tumor formation [52]. Interestingly, tumor 
size was decreased and growth inhibited in established tumors in mice when a shRNA 
against EZH2 was delivered. This indicates the promise that EZH2 holds as a 
candidate for cancer therapy [52]. 
 
Small interfering RNA (siRNA) duplexes4 targeted against EZH2 reduce the amounts 
of EZH2 protein present in prostate cells and also inhibit cell proliferation in vitro. 
Ectopic expression of EZH2 in prostate cells induces transcriptional repression of a 
specific cohort of genes. Small interfering RNA (siRNA) specific for EZH2 with the 
sequence GAGGUUCAGACGAGCUGAU, which has been previously identified by 
us to efficiently knockdown endogenous EZH2 expression in human cancer cells. 
 
miR-101 could interact with 3‟UTR of EZH2, we examined if the EZH2 transcript 
and protein levels can be repressed by miR101 overexpression. miR101 down 
regulates EZH2 protein expression in prostate cell line as well as breast cell line 
which have high endogenous EZH2 expression [35]. 
  
3. OBJECTIVE 
As mentioned above that the level of expression of EZH2 is often high  in many 
cancers like prostate, breast, liver, colon etc. Deregulation of PcG activities in human 
tumors has direct oncogenic effects and results essential for cancer cell proliferation. The 
mechanistic contribution of the PRC2 complex is not clear till this day; still 
H3K27me3 and DNA methylation play a role together in gene silencing by loss of 
tumor suppression. 
To investigate the role of EZH2 in H3K27me3 which leads to the recruitment of 
HDACs and DNMTs for the hypermethylation of the promoter of the target genes we 
have to measure the expression level of the particular gene of the enzyme. 
So my objective is “to compare the expression level of Histone methyltransferase-
EZH2 and its partner SUZ12 in cancer tissues and normal tissue”. 
  
  
4. MATERIALS AND METHODS 
The Human blood was collected from CWS Hospital, Rourkela as normal human 
tissue and Gall bladder and Lymph node cancer tissues were collected from Calcutta 
Medical College, Kolkata. 
4.1. Total RNA isolation 
Reagents and Buffers:- 
 TRIzol Reagents (Sigma), 
 Choloroform, 
 Isopropanol, 
 Ethanol (70%), 
 Denaturation Buffer 
 50 % deionized formamide, 
 2.2 M formaldehyde, 
 MOPS buffer (pH 7.0), 
 6.6 % glycerol, 
 0.5 % bromphenol,  




 50-100 mg of tissue in a 2 ml tube with 1 ml TRIzol was transferred. 
 Homogenized for 60 sec in the polytron. 
 200 l chloroform was added. 
 It was mixed by inverting the tube for 15 sec. 
 Incubated for 3 min at room temperature. 
 Centrifuged at 12.000 g for 15 min. 
 The aqueous phase was transferred into a fresh Eppendorf tube. 
 500 l isopropanol was added. 
 Centrifuged at max. 12.000 g for 10 min in the cold room. 
 The pellet was washed with 500 l 70 % ethanol. 
 Centrifuged at max. 7.500 g for 5 min in the cold room. 
 The pellet was dried on air for 10 min. 
 Then the pellet was dissolved in 50-100 l DEPC-H2O. 
 Incubated for 10 min at 60 C. 
 Spectrophotometric reading was taken. 
 Analysed the RNA on a MOPS gel: 
 1-3 g RNA was dissolved in 11 l denaturation buffer. 
  
 1 l Ethidium bromide (1mg/ml) was added and denatured at 65 C for 
15 min 
 1 % agarose gel was loaded in MOPS buffer plus 5 % formaldehyde. 
 The gel was run at 40 V for 4 h. 
 
4.2. cDNA synthesis (rt-PCR) 
Regents and Buffer:- 
 5X First Strand Buffer 
 10mM dNTP Set 
 0.1M DTT 
 Random Primers 
 RNase OUT Ribonuclease Inhibitor 
 Super Script II RNase H- Reverse Transcriptase 
 
Protocol:- 
 8µl of total RNA were taken. 
 Then 3 μl Random Primers was added. 
 1 μl dNTP mix was added. 
 Then vortex and spin downed tube. 
 Incubated at 65°C for 5 min. 
 Placed tube on ice. 
 4 μl 5X Buffer, 2 μl DTT and 1μl RNAseOut were added. 
 Then vortex and spin downed tube. 
 Incubated at 42°C for 1 min. 
 1μl SuperScript II RNase H- Reverse Transcriptase was added. 
 Incubated at 42°C for 60 min. 
 Incubated at 70°C for 15 min. 
 180 μl of molecular grade water was added. 
 Nanodrop 1000 was used to measure concentration. Set sample typesetting to 
Other Sample and the constant to 33. 
 Stored at -80°C. 
4.3. Gene specific PCR 
Used Primers:- 
Gene Forward Reverse 
EZH2 5‟-GCAGCCTTGTGACAGTTCGT -3‟ 5‟-CAGATGGTGCCAGCAATAGA -3‟ 
SUZ12 5′-ATTGCCCTTGGTGTACTCTGA-3′ 5′-GACATGCTTGCTTTTGTTCGT-3′ 
β- actin 5′-CCTGTACGCCAACACAGTGC-3′ 5′-ATACTCCTGCTTGCTGATCC-3′ 
(Tang H. et al., 2009) 
  
PCR mixture:- (Total 25µl) 
 0.2 µM dNTP- 0.5µl 
 1.5 mM MgCl2- 1.5µl 
 1x PCR Buffer- 2.5µl 
 Taq Polymearse (5U/µl) 
 Primer 0.2 µM- 0.5µl 
 cDNA- 2µl 








Denaturation 94 1 min 
2
nd
 Denaturation 94 20 sec 
Annealing 57 20 sec 
Extension 72 30 sec  













Blood 423.90 1.21 0.78 
Gall bladder 561.34 1.43 0.66 
Lymph node 511.09 1.18 0.92 
 
 






















Blood Gall bladder Lymph node 
EZH2 193.25 267.63 344.52 
SUZ12 206.12 259.02 325.79 
β- actin 221.34 218.09 213.88 
 
Purity of cDNA after PCR:- 
Geness Blood Gall bladder Lymph node 
EZH2 0.80 1.03 1.34 
SUZ12 0.78 0.96 1.22 
β- actin 0.99 0.89 0.76 
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A. L1- β- actin 
     L2- EZH2 
     L3- SUZ12 
B. L1- EZH2 
     L2- SUZ12 
      L3- β- actin 
C. L1- EZH2 
      L2- β- actin 
      L3- SUZ12 
      L4- DNA ladder 
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EZH2 and SUZ12 expressions are elevated in Lymph node Cancer:- 
It was well established fact that EZH2 over expressed in case of prostate and breast 
cancer, so we were interested in determining whether PcG complex (EZH2 and 
SUZ12) is dysregulated in lymph node cancer. Peripheral blood was taken as normal 
tissue and the expression level was compared with lymph node tumors, and we found 
that EZH2 and SUZ12 transcript was overexpressed significantly in lymph node 
tumor cells relative to normal. 
 
In agarose the band intensity of EZH2 in lymph node tumor is much higher as 
compare to blood and the spectrophotometry reveals that the expression level of 
catalytic subunit of PcG (EZH2) and its partner SUZ12 were overexpressed as their 
concentrations were 344.52 and 325.79 respectively. 
 
From the above result we can hypothesize that due to overexpression of these PcG 
complexes might be playing role in invasive lymph node cancer. 
 
Expressions of PcG complexes are normal in Gall bladder Cancer:- 
The band intensities of PcG complexes in case of gall bladder cancer were not so 
bright as compared to normal blood cells. The concentration of PcG transcripts were 
267.63 and 259.02 which was just above the normal expression range. This data 
reveals that PcG complexes are not overexpressed in case of gall bladder cancer. 
 
From the above result we can say that there is no abnormal role of PcG complexes 
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